ERBB2 and breast carcinoma: Breast cancer patients were more likely to develop IMD if they had triple-negative disease (OR 3.52 [3.10–3.99]), HR-/HER2+ disease (OR 2.72 [2.34–3.16]), or HR+/HER2+ disease (OR 1.67 [1.47–1.90]) compared with HR+/HER2- disease.